Eosinophilia and fluid retention in systemic administration of interleukin-2.

Kovach, JS; Gleich, Gerald J.

doi:10.1200/jco.1986.4.5.815

Cited by 18 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst IL-2 has no effect on degranulation, IL-2 together with the lymphocyte chemoattractant factor (LCF) has been shown to be by far the most potent eosinophil chemoattractant [40,55]. Systemic or intrapleural administration of IL-2 induced a significant eosinophilia in the peripheral blood [222][223][224] and pleural fluid [225], respectively. The migratory response of eosinophils is mediated by the high affinity IL-2 receptor as evidenced by the molar potency of IL-2 as an eosinophil chemoattractant and by the ability of monoclonal antibodies to inhibit IL-2-induced chemotaxis [40].…”

Section: Activation and Primingmentioning

confidence: 99%

Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part I)

Kroegel¹,

Virchow²,

Luttmann³

et al. 1994

Eur Respir J

129

View full text Add to dashboard Cite

P Pu ul lm mo on na ar ry y i im mm mu un ne e c ce el ll ls s i in n h he ea al lt th h a an nd d d di is se ea as se e: : t th he e e eo os si in no op ph hi il l l le eu uc co oc cy yt te e ( (P Pa ar rt t I I) ) ABSTRACT: Increasing evidence has accumulated to suggest that eosinophils play a key role in the pathogenesis of asthma and other pulmonary diseases by damaging infiltrated bronchial tissue and lung parenchyma. The first part of this review on eosinophils describes the cellular characteristics and properties of the cell, which help in understanding its role in disease. The article focuses on origin, maturation and differentiation of the eosinophil, its morphological and phenotypical properties, as well as its preformed and newly generated mediators of inflammation. The cause and putative significance of eosinophil heterogeneity in respect to function and density will also be discussed. In addition, the naturally occurring mediators through which eosinophils are activated and communicate with other inflammatory cells are outlined.The first part closes with new aspects of eosinophil recruitment from the circulation into perivascular tissue, including nonselective and putative selective adhesion mechanisms and chemotaxis.

show abstract

Section: Activation and Primingmentioning

confidence: 99%

Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part I)

Kroegel¹,

Virchow²,

Luttmann³

et al. 1994

Eur Respir J

129

View full text Add to dashboard Cite

show abstract

“…It was therefore postulated that eosinophilia induced by IL-2 might be responsible for fluid retention, which is one of the toxic effects of IL-2 therapy [13]. In our study, however, there was no relationship between eosinophilia and weight gain in cancer patients treated with this therapy.…”

Section: Discussionmentioning

confidence: 58%

“…Further, the in vivo generation of elevated levels of several cytokines was observed in the serum of cancer patients who had received IL-2 [3,9,18]. In addition, the serum concentration of TNFa has been reported to correlate with clinical response to IL-2 and LAK therapy in cancer patients [13]. Since IL-5 might be responsible for the eosinophilia induced by IL-2 injection, these results suggest that cytokine production by IL-2-stimulated lymphocytes may be related to the antitumor response of cancer patients treated with IL-2, as well as this therapy.…”

Section: Discussionmentioning

confidence: 98%

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

Arinaga

Karimine

Takamuku

et al. 1992

Cancer Immunol Immunother

View full text Add to dashboard Cite

On the basis of our clinical findings that the ability of cancer patients to generate lymphokine-activated killer cells became markedly augmented after mitomycin C administration, we designed a treatment regimen comprising mitomycin C 12 mg/m2, i.v. on day 1 and recombinant interleukin-2 700 U/m2 (8000 IU/kg), i.v. every 12 h from day 4 through day 8. The treatment course was repeated at almost 7-day intervals. Altogether 33 patients with advanced carcinoma, including mainly gastrointestinal carcinoma, were treated with this regimen. Of these, 10 had a partial response (PR) and 4 had a minor response (MR). Since eosinophil counts peaked 1 day after either the first or second course of the therapy, the posttreatment values were compared to each pretreatment level, with regard to the clinical antitumor response to this treatment. When patients who showed PR were defined as responders, absolute eosinophil counts and the percentage of eosinophils in responders after both the first and second courses of the therapy were significantly greater than each pretreatment value or the posttreatment level in nonresponders. Further, these findings were almost identical, when both PR and MR were considered to be a true remission and therefore patients who exhibited PR or MR were defined as responders, although the difference between posttreatment levels of eosinophils in responders and nonresponders was not significant at the second course. These results indicate that eosinophilia induced by this treatment correlates with the clinical response to this therapy.

show abstract

“…12 Furthermore, it has also been reported that rlL-2 administration as a part of immunotherapy for a malignant tumour induced marked eosinophilia. 14,15 These data still suggest a positive relationship between IL-2 and eosinophil accumulation.…”

Section: Discussionmentioning

confidence: 93%

Elevation of soluble interleukin‐2 receptor levels in nasal allergy

Hisamatsu

Ganbo

Nakazawa

et al. 1995

Mediators of Inflammation

View full text Add to dashboard Cite

To investigate soluble IL-2 receptor (sIL-2R) levels in nasal allergy, the sera and nasal secretions from patients with nasal allergy and from healthy subjects were subjected to a double-epitope enzyme-linked immunosorbent assay. Significant elevation of sIL-2R concentrations in the sera and nasal secretions was observed in the allergy patients (n = 26) compared with those of healthy subjects (n = 9). IL-2R-positive (CD25+) cells were observed in the crust formed in an allergic nasal mucosa. The concentration of sIL-2R in the sera correlated neither with the eosinophil count of the peripheral blood count nor with clinical severity. The concentration of sIL-2R in the nasal secretions was significantly higher compared with that in the sera from allergic patients (p < 0.01), whereas no significant difference was observed between sIL-2R levels in the sera and nasal sections from normal subjects. These findings indicate that sIL-2R plays an essential role in allergic processes by regulating IL-2R-positive cells recruited into the nasal mucosa.

show abstract

Eosinophilia and fluid retention in systemic administration of interleukin-2.

Cited by 18 publications

References 0 publications

Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part I)

Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part I)

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

Elevation of soluble interleukin‐2 receptor levels in nasal allergy

Contact Info

Product

Resources

About